Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Arcus closes $70mm oversubscribed Series B round

Executive Summary

Arcus Biosciences Inc. (immuno-oncology) raised $70mm through its oversubscribed Series B round. (The company's initial targeted amount was $50mm.) GV (Google Ventures) led and was joined by Invus, Taiho Ventures, DROIA Oncology Ventures, Stanford University (which holds investment rights under a technology license agreement), and existing investors The Column Group, Foresite Capital, Celgene, and Novartis AG.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies